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 INTRODUCTION 
   “Primum Non Nocere” 
   (First of all do no harm) 
       -THOMAS SYDENHAM 
 The term “Spinal Anaesthesia” was coined by Leonard 
Corning in 1885. 
 In 1898, the first deliberate spinal anaesthesia was given to 
August Karl Gustav Bier by his assistant Dr.Hildebrandt.  The 
second attempt was done on the theca of Dr.Hildebrandt.  Twenty 
three minutes after the injection of cocaine, Dr. Bier noted “A strong 
blow with an iron hammer against the tibia was not felt as pain.” 
 The simplicity of the technique of spinal anesthesia and its 
reliability had made it one of the preferred techniques in 
infraumbilical surgeries. 
 Bupivacaine when used alone intrathecally produces analgesia 
for three to four hours, making it unsuitable in cases where the 
duration of surgery is longer. 
 Different adjuvants such as opioids, clonidine or neostigmine 
may be added to enhance spinal anesthesia, though their use is 
limited because of side effects. 
Ketamine is a potent analgesic acting as an antagonist at N-
Methyl – D asparticacid receptor sites and has a local anaesthetic 
action.  Intrathecal ketamine has been used as a sole agent or in 
combination with local anaesthetics.  It provides stable 
haemodynamics but shorter duration of action.   
 Midazolam has a spinally mediated antinociceptive effect and 
enhance the analgesic effect of local anaesthetics when used 
intrathecally.  It improves the duration and quality of the spinal 
anaesthesia, though it does not prevent the haemodynamic instability 
produced by intrathecal bupivacaine. 
 Hence this study is done to evaluate the effect of small doses 
of ketamine and midazolam with bupivacaine intrathecally in terms 
of duration and quality of analgesia and side effect profile. 
 
 
 
 
 
 
 
  
 
 
 
 
AIM OF STUDY 
 
 The aim of this study is to evaluate the effect of low doses of 
ketamine and midazolam with bupivacaine intrathecally in terms of 
duration of analgesia and haemodynamic parameters. 
 
 
 
 
 
 
 
 
 
ANATOMY OF SUBARACHNOID SPACE 
 Subarachnoid block means the temporary interruption of nerve 
transmisssion within the subarachnoid space produced by injection 
of a local anaesthetic solution into cerebrospinal fluid. 
Applied anatomy of vertebral canal: 
 Vertebral canal extends from foramen magnum to the sacral 
hiatus. It protects the spinal cord. 
 
 The vertebral column comprises 33 vertebrae (7-cervical, 12-
thoracic, 5-lumbar, 5-fused sacral and 4-coccygeal) has four curves. 
Cervical and lumbar curves are convex anteriorly and thoracic & 
sacral curves are convex posteriorly. The curves of the vertebral 
column influences the spread of the local anaesthetic in the 
subarachnoid space. 
 
 Each vertebra is composed of a body separated from the 
adjacent vertebra by intervertebral disc and formed by pedicles and 
laminae, which surround and protect the cord laterally and 
posteriorly. 
 
 The vertebral column is bound together by several ligaments. 
They are, 
1. Supraspinal ligament – passes longitudinally over the tips of 
the spinous processes from C7 to the sacrum. 
2. Interspinous ligament – connects the adjoining spinous 
processes together.  
3. Ligamentum Flavum – composed of yellow elastic fibres 
known as yellow ligament, connects the adjacent laminae. 
They become progressively thicker from above downwards. 
4. Posterior longitudinal ligament – It is on the posterior surface 
of bodies of vertebrae. 
5. Anterior longitudinal ligament – It runs along the front of the 
vertebral bodies. 
There are seven projections from these vertebral (or) neural arches. 
They are, 
a) Three muscular processes–(2-Transverse processes, 1-spinous 
process for the attachment of muscle and ligaments). 
b) Four articular process – Two upper & two lower which in the 
lumbar region prevent rotation but allow limited flexion and 
extension between continuous vertebrae. 
Vertebral canal formed by these structures has deficiencies 
posteriorly in the midline called inter laminar foramina which 
enlarge in flexion accessible for the passage of spinal needle. The 
direction of spinous process determine the direction of spinal needle. 
SPINAL CORD: 
 It is the direct continuation of the medulla oblongata extending 
from the upper border of the atlas to the first lumbar vertebra below 
which there is leash of nerve roots termed cauda equina. Spinal 
nerves are 31 pairs totally. 
 8  –  Cervical 
 12  –  Thoracic 
 5  –  Lumbar 
 5  –  Sacral 
 1  –  Coccygeal          
 Each of the spinal nerve is composed of anterior and posterior 
roots uniting at the inter vertebral foramina and form a nerve trunk. 
Membranes covering the spinal cord are dura mater, arachnoid mater 
and piamater. Dura and arachnoid mater end at S2 level. Piamater is 
closely applied to the spinal cord. 
 
BLOOD SUPPLY: 
 It is from the anterior spinal artery which is a branch of 
vertebral artery and also by a pair of posterior spinal arteries which 
arise from the posterior inferior cerebellar arteries. There is no 
anastamosis between these arteries. 
SPINAL VEINS: 
 The spinal veins are arranged into anterior and posterior 
plexus which are draining into vertebral, azygos and lumbar veins.        
CEREBROSPINAL FLUID: 
 This is an ultrafiltrate of the blood plasma from choroid plexus 
of the lateral ventricles with a pH of 7.32 (7.27-7.37) 
 It is a clear, colourless fluid found in the cranial and spinal 
subarachnoid spaces and in the ventricles of the brain. 
 The total volume of CSF in an average adult ranges from 120-
150ml of which 25-35ml is in the spinal subarachnoid space. 
Composition of cerebrospinal fluid: 
Specific gravity  - 1.006 (1.003-1.009) at 370C   
Pressure   - 60-80mm of water 
Pco2    - 48mmHg 
HCo3-   - 23meq/l 
Na+    - 133-145meq/l 
Ca+    - 2-3meq/l 
Po4-    - 1.6mg/dl 
Mg+    - 2-2.5mg/dl 
cl-    - 15-20mg/dl 
Protein   - 23-38mg/dl 
Sugar   - 45-80mg/dl 
Lymphocytes  - 0-5cells/cmm 
 An important factor that determine the spread of drug in 
cerebrospinal fluid is the specific gravity of the drug in relation to 
that of cerebrospinal fluid (Baricity) which is 1.003-1.009. Hyper 
baric solution is one which is denser than CSF at 370C.  
 
 
 
 
PHYSIOLOGY OF SUBARACHNOID BLOCK 
 Subarachnoid block implies the temporary interruption of 
nerve transmission within the subarachnoid space by injections of 
local anaethetics. The blockade of nerve fibres occur in the order of 
temperature, pain, proprioceptive and then motor fibres.   
 
FACTORS INFLUENCING HEIGHT OF BLOCKADE: 
a -  Site of injection  
b -  Angulation of needle  
c -  Characteristic of local anaesthetic - baricity 
d - Dose of local anaesthetic 
e - Position of the patient during and after injection 
f - Anatomic configuration of spinal column. 
g - Patient height (at extrems) 
h - Volume of cerebrospinal fluid 
i - Reduced cerebrospinal fluid with increased intra abdominal  
  pressure (eg. Pregnancy) 
 
 
 
a) Effects on Cardio Vascular System:    
 Most important physiological response to subarachnoid block 
involve cardio vascular system due to combined effect of autonomic 
denervation, higher level of neural block, added effect of vagal 
innervation.  
 Local anaesthetics and vasoactive substances administered in 
small doses intrathecally leads to direct cardiovascular effect. 
 Level of sympathetic denervation determines the magnitude of 
cardio vascular system responses, but the relationship is neither 
predictable nor precise. 
 Sympathetic denervation produces arterial and more 
physiologically important arteriolar dilatation and vasodilatation in 
the venous circulation produces fall in blood pressure. 
 Due to Bainbridge reflex, the fall in blood pressure is 
associated with bradycardia, blockade of cardiac sympathetic fibre 
from T1-T4 is an additional factor that causes bradycardia.  
b) Effects on Respiratory System: 
 Respiration is not depressed normally. High spinal can cause 
paralysis of intercostals muscles but resting tidal volume, maximum 
inspiratory volume, respiratory rate, arterial blood gas, negative 
intrapleural pressure and also the phrenic nerve are unaffected. 
Hypoxia may accompany hypotension and is corrected by oxygen 
administration via face mask. 
c) Gastro Intestinal Effect: 
 Preganglionic fibres from T5-L1 are inhibitory to gut. So in 
sympathetic blockade the small intestine contracts with relaxed 
sphincters and peristalsis remains normal. Handling of viscera 
causes discomfort and bradycardia since vagus is not blocked. 
d) Hepatic and Renal Effects: 
 The hepatic blood flow decreases and is directly proportional 
to the decrease in blood pressure. There may be normal hepatic 
oxygen extraction. Renal blood flow is maintained by autoregulation 
and does not decrease till mean arterial pressure goes below 
50mmHg. 
e) Genito Urinary System:           
 Sphincters of bladder are not relaxed, and tone of the ureter is 
not greatly altered. Urinary retention occurs. Penis is often engorged. 
Uterine tone is unchanged in pregnancy. In the absence of 
hypotension spinal anaesthesia has got no effect on the progress of 
labour and uterine blood flow.  
 f) Metabolic and hormonal effect: 
 Spinal anaesthesia blocks hormonal and metabolic responses 
to nociceptive stimuli arising from the operative site. It minimizes 
the rise in blood sugar, cortisol, catecholamines, renin and 
aldosterone release associated with stress. Post operative negative 
nitrogen balance and secretion of antidiuretic hormone are inhibited.  
g) Thermo Regulation: 
 Hypothermia results from heat loss to the cold environment 
due to vasodilatation. 
 
PHARMACOLOGY OF DRUGS 
a) Bupivacaine: 
 Bupivacaine is an amide linked local anaesthetic. It is a 
hydrochloride salt of d(1)-1-butyl N-(2’6’ dimethylphenyl) 
piperidine – 2 - carboxamide and is presented as a racemic mixture. 
¾ It was synthesized by EO af Ekenstem. 
¾ First reports of its use was published in 1963 by Telivuo. 
¾ It is derived from Mepivacaine and is very stable compound 
and may be autoclaved repeatedly. 
Pka is 8.1 
MW     -  288  
Protein binding    -  95% 
Lipid solubility   -  28 
Elimination half life  -  210 minutes 
Toxic plasma concentration -  >1.5μg/ml 
Approximate duration of action-  175minutes 
Availability: 
 Ampoule - 0.5% Bupivacaine hydrochloride 4cc 
          0.5% Bupivacaine hydrochloride with dextrose (heavy) 4cc 
 Vials  - 0.25% and 0.5% Bupivacaine hydrochloride 20cc 
 Dosage - Maximum dosage 3mg/kg body weight. 
Uses: 
¾ Spinal anaesthesia 
¾ Epidural anaesthesia 
¾ Caudal anaesthesia 
¾ Continuous epidural anaesthesia 
¾ Peripheral nerve block 
Onset time and duration of action 
Site of action Onset (minutes) Duration (minutes) 
Intrathecal  5 180-240 
Epidural 15-20 165-225 
Brachial plexus 15-20 600 
 
Pharmacokinetics: 
 Once injected intrathecally, it gets absorbed by the nerve 
rootlets and results in the desired effect. It is rapidly absorbed from 
the site of injection, but the rate of absorption depends on the 
vascularity at the site and presence of vasoconstrictors. 
 High lipid solubility of bupivacaine makes it easy for nerve 
and vascular tissue penetration. 
 80-95% of the absorbed bupivacaive binds to the plasma. 
 
Distribution: 
 Rapid distribution phase: (α) 
 In this phase the drug is distributed to highly vascular region 
t1/2 of α  - being 2.7 minutes.      
 Slow disappearance phase: (β) 
 In this phase the drug distributes to slowly equilibrating tissues 
t1/2 of β – being 28minutes.  
 Biotransformation and excretion phase δ  
 T1/2 of δ is 3.5hours and clearance is 0.47 litre/minute. 
Biotransformation: 
 Possible path ways of metabolism of bupivacaine include 
aromatic hydroxylation and conjugation. Only the N-dealkylated 
metabolite, N-desbutyl bupivacaine has been measured in blood (or) 
urine after epidural (or) spinal anaesthesia. Alpha1 acid glycoprotein 
is the most important plasma protein binding site of bupivacaine and 
its concentration is increased by many clinical situations including 
post operative trauma. 
Excretion: 
 It is through the kidney, 4-10% of the drug is excreted 
unchanged. 
Mode of Action: 
a) Site of action: 
i) The spinal nerve rootlet fine nerve filaments having a large 
surface area are exposed to the local anaesthetics.  
ii) Posterior and lateral aspects of the spinal cord itself. 
b) Sodium Channel blockade: 
 They impede sodium ion access to the axon interior by 
occluding the transmembrane sodium channels thus delaying the 
process of depolarisation and axon remains polarized. It is a non-
depolarisation blockade.     
Pharmacodynamics: 
 It has got a longer duration of action but a slower onset. 
Cardio vascular system: 
 It reduces cardiac output by reducing the sympathetic tone, by 
slowing the heart rate and by reducing the venous return, it produces 
a fall in arterial blood pressure but it is relatively slow and is seldom 
very profound. 
 It produces a fall in central venous pressure. It causes an 
increase in lower limb blood flow and reduction in incidence of deep 
vein thrombosis. 
Respiratory System: 
 Spinal blockade seldom, if ever causes respiratory problem. 
Gastro intestinal tract: 
 There is an increase in gastro intestinal motility and emptying 
of the gastric contents are better.   
 Toxicity: 
 Toxicity is related to plasma level of unbound drug and more 
likely due to an inadvertent intravenous injection. Systemic toxicity 
reactions primarily involve central nervous system and cardio 
vascular system. The blood level required to produce central nervous 
system toxicity is less than that required to produce circulatory 
collapse.  
Central Nervous System Toxicity:    
 Initial symptom includes feeling of light headedness and 
dizziness, followed by visual and auditory disturbances. Objective 
signs are excitatory and includes shivering, muscle twitching and 
tremor. Ultimately generalized tonic, clonic seizures occurs. 
Cardiovascular System Toxicity: 
 The rate of depolarization in fast conducting tissue of purkinje 
fibres and ventricular muscle is decreased. The rate of recovery of 
bupivacaine induced block is slower than that of lignocaine. 
Extremely high concentration of the drug causes sinus bradycardia 
and cardiac arrest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGY OF KETAMINE 
History : 
 Ketamine was synthesized in 1962 by Stevens and was first 
used in human in 1965 by Corssen and Domino.  Ketamine differs 
from most other drugs used to induce anaesthesia because it has a 
significant analgesic effect.  Ketamine has 2 stereoisomers, S(+), and 
R (-).  The S(+) is more potent and is associated with fewer side 
effects.  Ketamine is a phencyclidine derivative. 
 
Physicochemical Characteristics : 
 Ketamine has a molecular weight of 238 KD, is partially water 
soluble with a PK of 7.5. 
Mechanism of action : 
 Ketamine binds non competitively to the phencyclidine 
recognition site on N-methyl D-aspartate (NMDA) receptors.  
Ketamine may exert effects at other sites including opioid receptors, 
monoaminergic receptors, muscarinic receptors and voltage – 
sensitive sodium and L type calcium channels. 
 
 
NMDA Receptor Antagonism :   
Ketamine inhibits activation of NMDA receptors by 
glutamate, decreases the presynaptic release of glutamate and 
potentiates the effects of inhibitory neurotransmitter GABA. 
Opioid receptors : 
 Ketamine has been reported to interact with mu, delta, and 
kappa opioid receptors. 
Sodium channels : 
 Consistent with its mild local anaesthetic like properties 
ketamine interacts with voltage gated sodium channels. 
Muscarinic receptors : 
 Ketamine has an antagonist effect at the muscarinic receptors. 
Mono aminergic receptors : 
 The antinociceptive action of ketamine may involve 
descending inhibitory monoaminergic pathways. 
PHARMACOKINETICS  
 Ketamine has a rapid onset of action, relatively shorter 
duration of action and high lipid solubility.  Peak plasma 
concentrations of ketamine occur within 1 minute after iv 
administration and within 5 minutes after intramuscular 
administration.  Ketamine has a high hepatic clearance rate (1litre 
/minute) and a large volume of distribution (3 litres / kg) resulting in 
an elimination half time of 2-3 hrs. 
CLINICAL USES : 
1.  ANALGESIA 
¾ Ketamine is a unique drug evoking intense analgesia at 
subanaesthetic doses. 
¾ The analgesic effects of ketamine are primarily due to its 
activity in the thalamic and limbic systems, which are 
responsible for the interpretation of painful signals. 
¾ Small doses of ketamine are also useful adjuvants to opioids 
analgesia 
¾ Spinal cord sensitization is responsible for pain associated 
with touching or moving an injured part. 
¾ Control to the development of spinal cord sensitization in the 
spinal cord dorsal horn. 
2. Neuraxial Analgesia : 
¾ Epidural or intrathecal administration of ketamine produces 
analgesia without depression of ventilation. 
¾ The affinity for spinal opioid receptors may be 10,000 fold 
weaker than that of morphine. 
¾ Intrathecal administration of ketamine produces variable and 
brief analgesia. 
3. Induction of Anaesthesia : 
 Administration of 1-2 mg/kg IV on 4-8mg/kg IM injection of 
ketamine produces induction of anaesthesia.  Consciousness is lost 
in 30-60 seconds after IV administration and in 2 to 4 minutes after 
IM injection.  Ketamine is a beneficial drug for induction in patients 
with hypovolemia and bronchial asthma. 
4.  Sedation : 
 Ketamine in subanaesthetic dose (<1.0mg/kg) is used for 
sedation. 
SYSTEMIC EFFECTS : 
Central nervous system : 
1. Ketamine increases cerebral blood flow and cerebral 
metabolic rate and oxygen consumption. 
2. Ketamine increases intracranial pressure.  Prior 
administration of thiopental, diazepam, midazolam has been 
shown to blunt ketamine induced cerebral blood flow. 
3. Ketamine’s effect on EEG are characterized by abolition of 
alpha rhythm and dominance of theta activity. 
Cardiovascular system : 
1. Ketamine produces cardiovascular effects that resemble 
sympathetic nervous stimulation.  A direct negative inotropic 
effect is usually over shadowed by central sympathetic 
stimulation. 
Ventilation and Airway : 
1. The ventilatory response to carbondioxide is maintained 
during ketamine anaesthesia and the PaCO2 is unlikely to 
increase > 3mm Hg. 
2. Apnea can occur if the drug is administered rapidly by 
intravenous route, 
3. Upper airway reflexes remain relatively intact. 
4. Salivary and tracheobronchial mucous gland secretions are 
increased by IV or IM administration of ketamine. 
Bronchomotor Tone : 
 Ketamine has bronchodilatory activity.  Ketamine has been 
used in subanesthetic doses to treat bronchospasm in the operating 
room and intensive care unit. 
Uses of doses of ketamine : 
Induction of General anaesthesia : 
0.5- 2 mg / kg IV 
4 – 6 mg / kg IM 
Maintenance of General anaesthesia 
0.6-  1 mg / kg IV 
15 - 45 mg/kg / min IV with N2O inO2 
30 – 90 mg/kg / min IV without N2O 
Sedation and Analgesia : 
 0.2 – 0.8 mg / kg IV over 2-3 min 
 2 – 4 mg / kg IM 
Preemptive / Preventive analgesia 
 0.15 – 0.25 mg / kg IM 
Side effects and Contraindications : 
1. Ketamine produces emergence reactions. Common 
manifestation are vivid dreaming, extra corporeal experiences 
and illusions. These incidents are often associated with 
excitement, confusion, euphoria and fear. 
2. Ketamine increases cerebral blood flow and is contraindicated 
in patients with raised intracranial pressure. 
3. It is contraindicated in patients with open eye injury or other 
conditions with  raised intraocular pressure. 
4. Ketamine’s preservative chlorbutanol is neurotoxic 
5. Ketamine is avoided in patients with psychiatric disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHARMACOLOGY OF MIDAZOLAM 
 
  Midazolam is an imidobenzodiazepine, water soluble 
benzodiazepine. Benzodiazepines were introduced in early 1960s. 
Diazepam, the most popular drug of this group for the past 2 
decades, is water insoluble, has a prolonged effect and is painful 
during injection. The unique chemical structure of midazolam 
confers a number of physicochemical properties that distinguish it 
from other benzodiazepines. This drug was synthesized in 1976 by 
Tryer and walser. 
CHEMISTRY: 
  Benzodiazepines are so called because they consist of a 
benzene ring fused with a seven member diazepine ring. Various 
modification in the structure of the ring systems have yielded 
compounds with similar activities. 
  Midazolam with molecular weight of 362, has a fused 
imidazole that is different from classic benzodiazepines. The 
imidazole ring accounts for the stability of an aqueous solution and 
rapid metabolism. The ring exhibits a pH dependent ring opening 
phenomenon. The ring opens at pH less than 4 making the drug 
soluble in aqueous solution. Once midazolam enters the body, the 
pH changes to 7.4 and drug assumes closed ring structure and 
becomes highly lipid soluble. Midazolam is the most lipid soluble 
benzodiazepine. 
PHARMACOKINETICS: 
  Midazolam is rapidly absorbed from gastro intestinal 
tract, but only 50% of the orally administered drug enters the 
circulation, as substantial portion is metabolized during the first 
hepatic flow. Thus the oral dose is twice as high as intravenous dose. 
  Peak plasma concentrations are seen within an hour of 
ingestion. When given intramuscularly, the absorption is more 
predictable than diazepam. Being highly fat soluble it crosses blood 
brain barrier more easily than diazepam, to gain access to the 
receptors. It has a more rapid onset of action. After intravenous 
administration of midazolam to healthy adults the disappearance of 
midazolam from the plasma proceeds in two distinct phases. The 
initial phase of rapid disappearance is principally due to distribution 
of the drug while the final and slower phases of disappearance is 
attributable mainly to biotransformation. The volume of distribution 
of midazolam averages between 1 and 2.5 1/kg. Midazolam is tightly 
bound to plasma protein. After distribution equilibrium is reached, 
elimination half-life varies from 1 to 4 hours. Midazolam is 
metabolized mainly by hepatic microsomal oxidative mechanism, by 
a process of hydroxylation. The fused imidazole ring is oxidized 
very rapidly to both 1 and 4 hydroxy midazolam. Both these 
products are conjugated to glucuronides and are excreted in the 
urine. The metabolites have less than 1% activity of the parent drug. 
MECHANISM AND SITE OF ACTION: 
 An important inhibitory neurotransmitter in the brain is  
gamma amino butric acid (GABA), while glycine is the major 
inhibitory neurotransmitter in the spinal cord and brainstem. The 
benzodiazepines augment GABA thus producing sedation and 
anticonvulsant activity, while anxiolysis and muscle relaxation 
appear to be due to glycine mimetic effects  in  the spinal cord and 
brainstem. 
  Among the benzodiazepines midazolam has the greatest 
affinity for the receptors, but dissociate faster from the receptor, thus 
accounting for the rapid onset and shorter duration of action. Given 
intrathecally or epidurally, midazolam produces analgesia which is 
GABA mediated. Muscle relaxation produced by midazolam is due 
to potentiation of glycine action on the anterior horn cells. 
PHARMACODYNAMICS: 
CENTRAL NERVOUS SYSTEM: 
 Midazolam has anxiolytic, hypnotic, anticonvulsant, muscle 
relaxant and anterograde amnestic properties. It decreases the 
cerebral metabolic rate and cerebral blood flow. Cerebral perfusion 
pressure decrease as the systemic pressure falls more than the 
intracranial pressure. Given in doses of 0.25mg/kg it does not alter 
intracranial tension and therefore it can be used for neurosurgical 
procedures.  Emergence from induction is more rapid than, 
diazepam, but not so, when compared with thiopentone.  Midazolam 
decreases the anaesthetic requirement of inhalational agents. 
CARDIOVASCULAR SYSTEM: 
Midazolam decreases the myocardial contractility and 
systemic vascular resistance and causes vasodilatation, thus causing 
fall in arterial pressure.  The fall in blood pressure is similar to that 
caused by hypnotic doses of thiopentone, greater than that caused by 
equipotent does of diazepam and less than that caused by propofol. It 
increases the heart rate.  Midazolam does not abolish the stress 
response to intubation, but the increase in heart rate and blood 
pressure are less than with diazepam.  Midazolam does not alter 
coronary vascular resistance and does not cause coronary steal 
phenomenon. 
RESPIRATORY SYSTEM: 
Midazolam causes dose dependent depression of ventilation.  
In doses used for premedication or sedation,it does not alter the 
carbondioxide  response, but in doses above 0.2mg/kg it causes 
respiratory depression.  Apnoea produced by midazolam is dose 
related and is more common in patients premedicated with opioids, 
in chronic obstructive pulmonary disorder patients and following 
faster injection of the drug.  Their respiratory depression is reversed 
by flumazenil. 
INTRATHECAL MIDAZOLAM: 
  It is an agonist at the benzodiazepine binding site on a subunit 
of the pentameric GABAA receptor.  This receptor is a chloride-
inophore that, when activated typically stabilizes the transmembrane 
potential at or near the resting potential.  In neurons this typically 
serve to decrease the excitability. In primary afferent terminals, a 
modest depolarization is observed that serves paradoxically, to 
reduce the transmitter release, a form of presynaptic inhibition.  
Consistent with these effects and benzodiazepine subunit expression 
in dorsal root ganglia and on spinal neurons, benzodiazepine tends to 
suppress afferent evoked excitation in the substantia gelatinosa and 
motor horn. 
DRUG INTERACTIONS: 
 Erythromycin, clarithromycin  and fluconazole increase the 
effect of midazolam due to inhibition of cytochrome P450 III A 
enzyme. H2 receptor antagonist also inhibit cytochrome P450 III A 
enzyme. Aspirin and probenecid increase the effect by competing for 
protein binding site. Phenytoin, rifampicin and xanthines decrease  
the efficacy of midazolam due to increased metabolism by inducing 
cyto chrome P450. 
SIDE EFFECTS: 
 Nausea and vomiting are minimal. Incidence of hiccough is 
5.6%, cough is 1.5%. 
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intrathecally in rabbits for 14 consecutive days and concluded 
that even repeated injections lacked any neurotoxic effect. 
Anaesthesia Analgesia 2003 : 96, 
4. Brion and Hawksworth and colleagues observed psychomimetic 
manifestations in 50% and 30% of their patients while using 
intrathecal ketamine in doses of 50 mg and 0.75 – 0.9mg/kg 
respectively. Regional Anaesthesia 1992 : 69 
5. Togal and colleagues used ketamine in low doses (0.1mg/kg) 
and did not come across any side effects. This was done for 
prostate surgery in elderly patients.  European Journal of 
anesthesia 2004 : 21. 
6. Bharti and colleagues had found that post operative pain scores 
were lower in patients who received intrathecal midazolam 
(1mg) along with bupivacaine. Acta Anaesthesiology 
Scandinava 2003 : 47. 
7. Kim and colleagues used intrathecal midazolam in doses of 1 
and 2 mg along with bupivacaine and found that the duration of 
post operative analgesia was significantly prolonged and was 
dose dependent. British Journal of Anaesthesia 2001 : 86. 
8. Tucker and colleagues in a cohort study, evaluated 574 patients 
who received intrathecal midazolam and then observed them for 
one month for a wide range of symptoms related to 
neurotoxicity. They concluded that administration of intrathecal  
midazolam upto 2 mg did not increase the occurrence of 
neurological symptoms. Anaesthesia Analgesia 2003 : 96 
9. Addition of intrathecal midazolam to bupivacaine produces 
better post operative analgesia without prolonging recovery. The 
study was done in PG1 chandigarh for knee asthroscopy 
surgeries. 
10. Prakash and colleagues from Vardhman Mahavir Medical 
College, New Delhi, used 2 doses of midazolam  1mg and 2 mg 
with Bupivacaine intrathecally for patients undergoing 
caesarean section.  The mean duration of post operative 
analgesia was 6.1 hours in 2 mg midazolam group, 4.3 hours in 
1 mg midazolam group and 3.8 hrs with plain bupivacaine 
group. 
11. The analgesic and sedative effects of intrathecal midazolam in 
perianal surgeries was reported in European Journal of 
anaesthesiology, Aug 2004. 
12. Intrathecal midazolam combined with low dose bupivacaine 
improves postoperative recovery in diabetes patients undergoing 
foot debridment. This is reported in Acta Anaesthesiology 
Dec.2007.  
13. Intrathecal midazolam in combination with intrathecal fentanyl 
for labor pain is published in Anaesthesia Analgesia, June  
2004. 
14. Improvement in postoperative pain relief with the addition of 
midazolam to an intrathecal injection of buprenorphine and 
bupivacaine.  This is published in European Journal of 
Anaesthesiology, Nov 2003. 
15. Midazolam can potentiate the analgesic effect of intrathecal 
bupivacaine on thermal or inflammatory induced pain.  This is 
reported in Anaesthesia Analgesic, May 2003. 
16. Combination of low doses of intrathecal ketamine and 
midazolam with bupivacaine improves post operative analgesia 
in orthopaedic surgery.  This study was done by T. Murali 
Krishna and colleagues from PG1, Chandigarh and published in 
European Journal of Anesthesiology 2008 ; 25 ; 299-306. 
17. Yang CY,WongCS, ChangTY, Host. Intrathecal Ketamine 
reduces morphine requirements in patients with terminal cancer 
pain.Miller 6th edition. 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
¾ Approval  from the Ethical Committee was obtained 
¾ Written informed consent was taken from all patients 
¾ Patients with physical status ASA I and ASA II were included 
in this prospective double blind study. 
¾ Infra umbilical surgeries like herniorrhaphy, varicose vein 
surgery, orthopaedic surgeries with less than 3 hr duration 
were taken up for the study. 
¾ Morbidly obese patients, pregnant women, patient with 
neurological disease or any contraindication for regional 
technique were excluded from the study. 
Three groups were selected.  Patients were randomly assigned 
to one of the three groups.  Patients and anaesthesiologist were 
blinded to the test drug.  The volume of the test drug was kept 3.5 ml 
in all patients. 
 After attaching the patients to monitors, baseline values of 
heart rate, systolic, diastolic, mean arterial pressure and oxygen 
saturation were noted.  They were preloaded with 10ml/kg 
intravenous crystalloid solution. 
PROCEDURE : 
 Under strict aseptic precaution, lumbar puncture was 
performed at L3-L4 interspace using a 25-G Quincke’s needle. 
 After achieving free flow of cerebrospinal fluid the study drug 
was injected into the subarachnoid space. 
Study Groups : 
 Each study group consisted of 30 patients.  Patients in all 3 
groups received 3 ml of bupivacaine (heavy) 0.5%.  In addition, 
patients in group B received preservative free ketamine 0.1 mg/kg 
and those in group C received preservative free ketamine 0.1mg/kg 
and midazolam 0.02 mg/kg intrathecally.  The exact amount of 
ketamine and midazolam were measured using a tuberculin syringe 
and the final volume of the test drug in all the groups was made up 
to 3.5 ml by adding normal saline. 
PARAMETERS : 
Heart rate, non invasive blood pressure and SPO2 were 
measured at 2.5 min interval of the drug injection for the first 20  
min and thereafter every 10 min until the end of the surgery.  Any 
decrease in MAP below 20% of the baseline or systolic pressure less 
than 90mmHg was treated with a bolus dose of ephedrine (6 mg). 
SENSORY BLOCKADE: 
 Sensory blockade was assessed by pin prick in the mid axillary 
line at 1 min intervals until the level of block reached T10.  The 
maximum height of the sensory blockade was noted at 20 min. 
 Onset of sensory block was defined as the time taken from 
injection of drug to sensory block at T10 and  offset of sensory block 
was assumed when pinprick sensation at the S2 dermatome has 
returned. Duration of sensory block was defined as the time interval 
between onset of sensory block at T10 to regression of sensory block 
to S2. 
MOTOR BLOCKADE : 
 Motor block was assessed by the Modified Bromage score. 
 0 - No motor loss 
 1 - Inability to flex hip 
 2 - Inability to flex knee joint 
 3 - Inability to flex ankle 
 This was assessed at 1 min interval until complete motor 
blockade occurred.  Onset of motor block was defined as the time 
taken from injection of drug to development of complete motor 
block.  (Bromage Score-3). Bromage score ‘0’ was considered as 
complete recovery from motor block.  Duration of motor block was 
defined as time taken from onset of complete motor block to 
complete recovery of motor block. 
PAIN : 
 Pain was assessed by an 11 point verbal rating scale (Score 0 – 
10) which was explained to the patient preoperatively.  If any patient 
complained of pain at any time in the intraoperative period, he / she 
was given general anaesthesia and was excluded from the study. 
 Post operatively pain was assessed at 2 hour interval for the 
first 12 hours and then at 4 hour interval for 24 hours.  Rescue 
analgesia in the form of Inj. Tramadol 100 mg IM was given if the 
pain score was equal to or more than 4.  Duration of pain free period 
was measured from the time of spinal administration of the drug to 
the time when the patient needed the first rescue analgesia drug.  The 
total number of doses of rescue analgesic requirement in 24 hr was 
also noted. 
SEDATION : 
 The level of sedation of the patients was assessed by the 
Ramsay sedation score. 
 
 1 - Anxious and agitated 
 2 - Co-operative 
 3 - Asleep but brisk response to loud voice 
 4 - Asleep with sluggish response to loud voice 
 5 - No response to loud voice 
 6 - No response to pain 
 It was assessed every 15 min after injecting the drug until the 
sedation score was 2.  All patients were followed after surgery upto 
24 hrs for any behavioural side effects, confusion, dizziness, 
nystagmus, nausea, vomiting or any neurological complications like 
numbness or pain in the opposite leg, incontinence or retention of 
bowel or bladder or genital dysaesthesias. 
The main end points of our study were 
1. Postoperative pain free interval 
2. Haemodynamic stability shown in terms of requirement of 
ephedrine to treat hypotension. 
3. Any neurological complication in 24 hrs. 
Statistical Tools : 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package (EPI 2008).  
 Using this software range, frequencies, percentages, means, 
standard deviations, chi square and  'p'  values were calculated. Kruskul 
Wallis chi-square test was used to test the significance of difference 
between quantitative variables and Yate’s test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant relationship. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
OBSERVATION AND RESULTS 
 
In this randomized double blind study conducted in 90 
patients, the subjects were allocated in to three groups. 
Group A - Inj. 0.5% Bupivacaine 3ml  + 0.5cc Normal saline 
Group B - Inj. 0.5% Bupivacaine 3ml + 0.1mg/kg ketamine +  
   upto 3.5 ml with normal saline   
Group C - Inj.0.5%Bupivacaine 3ml +0.1mg/kg ketamine 
+0.02mg/kg of midazolam + upto 3.5 ml with normal saline   
DEMOGRAPHIC DATA: 
 All 3 groups were comparable in age, height, weight, duration 
of surgery.  
 
 
 
 
 
  
Table  1 :  Age distribution 
 
Group A Group B Group C Age 
Group No. % No. % No. % 
Upto  30 yrs 7 23.3 2 6.7 4 13.3 
31-40 16 53.3 20 66.7 6 20 
41-50 5 16.7 7 23.3 10 33.3 
>50 2 6.7 1 3.3 10 33.3 
Total 30 100 30 100 30 100 
Range 
Mean 
SD 
26-63 yrs 
37.93 
8.87 
28-60 yrs 
38.77 
6.94 
23-61 yrs 
41.67 
10.6 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.1433 Not Significant 
0.5042 Not Significant 
0.0721 Not Significant 
0.1425 Not  Significant 
  
In all the three groups the mean age were comparable and they 
are not statistically significant. 
 
  
Table  2:  Sex distribution 
 
Group A Group B Group C Sex 
distribution No. % No. % No. % 
Male 24 80 21 70 25 83.5 
Female 16 20 9 30 5 16.5 
Total 30 100 30 100 30 100 
‘P’ value for 
A & B 
A & C 
B& C 
 
0.556 Not Significant 
0.7408 Not Significant 
0.3598 Not  Significant 
 
 In all  the three groups the sex distribution were comparable 
and they are not statistically significant.                                             
 
 
 
 
  
 
Table 3  : Weight 
 
Weight Group A Group B Group C 
Range 48-75 45-72 50-76 
Mean 59.4 62.7 62.9 
SD 7.8 6.7 7.4 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.1 Not Significant 
0.056 Not Significant 
0.0726 Not  Significant 
0.9823 Not  Significant 
 
 In all the three the mean weight were comparable and they are 
not statistically significant. 
 
 
  
 
TABLE - 4 :   ASA PHYSICAL STATUS 
 
Group A Group B Group C ASA 
No. % No. % No. % 
I 23 76.7 25 83.3 25 83.3 
II 7 23.3 5 16.7 5 16 
‘P’ value for 
A & B 
A & C 
B& C 
 
0.7469 Not Significant 
0.7469 Not Significant 
0.1.0 Not  Significant 
 
 The ASA physical status in all the three groups were 
comparable and they are not statistically significant. 
 
 
 
 
 Table - 5  : Onset of Sensory Block (minutes) 
Onset of 
Sensory Block 
Group A 
 
Group B 
 
Group C 
 
Range 4.5-6.5 3.5-10 3-5 
Mean 5.55 7.2 3.92 
SD 0.54 2.04 0.5 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
0.0033 Significant 
0.0001 Significant 
0.0001  Significant 
 
 In group A the mean onset of sensory block is 5.55 minutes 
In group B the mean onset of sensory block is 7.2 minutes 
In group C the mean onset of sensory block is 3.92 minutes 
With addition of midazolam and ketamine the mean onset of sensory 
block is quicker compared to other two groups. 
 
 
Table - 6  : Onset of Motor Block (minutes) 
 
Onset of 
Motor Block 
Group A 
 
Group B Group C 
 
Range 7.5-10 7.5-10 5.5-7.5 
Mean 8.55 8.55 6.78 
SD 0.63 0.63 0.6 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
1.0       Significant 
0.0001 Significant 
0.0001  Significant 
 
In group A the mean onset of motor block is 8.55 minutes 
In group B the mean onset of motor block is 8.55 minutes 
In group C the mean onset of motor block is 6.78 minutes 
With addition of midazolam and ketamine the mean onset of motor 
block is quicker compared to other two groups. 
 
 
  
Table - 7  : Maximum Sensory Level 
 
Group A Group B Group C Maximum 
Sensory 
Level 
No. % No. % No. % 
T2 - - - - 3 10 
T4 4 13.3 4 13.3 21 70 
T6 16 53.3 16 53.3 6 20 
T8 10 33.3 10 33.3 - - 
 
Maximum sensory level of T4 was reached in 13.3% of cases in Group A 
Maximum sensory level of T4 was reached in 13.3% cases in Group B 
Maximum sensory level of T4 was reached in 70% of cases in Group C 
With addition of Midazolam and ketamine the maximum sensory level 
and reached in higher compared to other two groups. 
 
 
 
 
 Table - 8  : Duration of Sensory Block 
 
Duration of 
Sensory Block
Group A 
 
Group B Group C 
 
Range 160-240 180-280 200-360 
Mean 199.7 207 266.3 
SD 17.3 21.4 41.6 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
1.2436 Not Significant 
0.0001 Significant 
0.0001  Significant 
 
In group A the mean duration of sensory block was 199.7 minutes 
In group B the mean duration of sensory block was 207 minutes  
In group C the mean duration of sensory block was 266.3 minutes 
With addition of ketamine and midazolam the duration of sensory 
block is prolonged compared to other two groups.  
 
 Table - 9  : Duration of Motor Block 
 
Duration of 
Motor Block 
Group A 
 
Group B Group C 
 
Range 100-180 150-240 160-240 
Mean 159.7 181.3 208.7 
SD 15.6 20.1 22.7 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
0.0001 Significant 
0.0001 Significant 
0.0001  Significant 
 
In group A, the mean duration of motor block is 159.7 minutes 
In group B, the mean duration of motor block is 181.3 minutes 
In group C, the mean duration of motor block is 208.7 minutes 
With addition of ketamine and Midazolam the mean duration of 
motor block is prolonged compared to other two groups. 
 
 Table - 10  : Duration of pain free Interval (in Minutes) 
 
Duration of Pain 
free Interval 
Group A 
 
Group B Group C 
 
Range 240-440 200-360 360-900 
Mean 303 296 473 
SD 57.4 32.5 136.2 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
1.0002  Significant 
0.0001 Significant 
0.0001  Significant 
 
In group A the mean duration of pain free interval is 303 minutes 
In group B the mean duration of pain free interval is 296 minutes 
In group C the mean duration of pain free interval is 473 minutes 
With addition of ketamine and Midazolam the mean duration of pain 
free interval is prolonged compared to other two groups. 
 
Table  11 :    Number of rescue analgesics 
Group A Group B Group C No. of rescue 
analysis No. % No. % No. % 
1 - - 13 43.3 30 100 
2 19 63.3 17 56.7 - - 
3 11 36.7 - - - - 
Range 
Mean 
SD 
2-3 
2.37 
0.49 
1-2 
1.57 
0.5 
1 
1.0 
- 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
0.0001 Significant 
0.0001 Significant 
0.0001 Significant 
 
In group A the number of rescue analgesics required were in a range of 2-3 
In group B the number of rescue analgesics required  were in a range of 1-2 
In group C the number of rescue analgesics required were in a range of 1 
With addition of ketamine and midazolam the number of rescue analgesics 
required are less compared to other two groups. 
  
Table 12 : Systolic Blood Pressure 
 
Systolic B.P. Group A Group B Group C 
Range 104-130 110-136 106-142 
Mean 117.6 120.1 122.2 
SD 7.7 5.2 10.1 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.1461 Not Significant 
0.2755 Not Significant 
0.0604Not  Significant 
0.3082 Not  Significant 
 
 In all three groups the mean systolic blood pressure was 
comparable and they are not statistically significant. 
 
 
 
Table -  13 : Minimum Systolic Blood pressure 
Minimum 
Systolic B.P. 
Group A Group B Group C 
 
Range 84-110 88-120 80-110 
Mean 95.4 104.7 94.9 
SD 8.0 8.3 8.0 
‘P’ value for 
A.B. &C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
0.0002 Significant 
0.9402 Not  Significant 
0.0001  Significant 
 
In group A the mean minimum systolic blood pressure is 95.4 mmHg 
In group B the mean minimum systolic blood pressure is 104.7 mmHg 
In group C the mean minimum systolic blood pressure is 94.9 mmHg 
The minimum systolic blood pressure in group A is comparable to group C 
The minimum systolic blood pressure in group B and C are not significant and 
this finding is an added  advantage to ketamine midazolam group. 
 In group B the fall in systolic blood pressure is less comparable to other 
two groups. 
 
 TABLE 14 :  Vasopressor 
 
Group A Group B Group C Vasopressor 
No. % No. % No. % 
Yes 16 53.3 4 13.3 14 46.7 
No 14 46.7 26 86.7 16 53.3 
‘P’ value for 
A & B 
A & C 
B& C 
 
0.0026 Significant 
0.7963 Not Significant 
0.0112 Not  Significant 
 
 The vasopressors required in group A and C were compared 
and they are not statistically significant.  In both these groups the 
vasopressor  requirement was comparable. 
 In group B the vasopressor requirement is less compared to 
other two groups. 
 
 
 
Table  15 :    Sedation Score 
Group A Group B Group C Sedation 
Score No. % No. % No. % 
1 5 16.7 - - - - 
2 25 83.3 8 26.7 7 23.3 
3 - - 22 73.3 23 76.7 
Range 
Mean 
SD 
1-2 
1.83 
0.38 
2-3 
2.73 
0.45 
2-3 
2.77 
0.43 
‘P’ value for 
A.B & C 
A & B 
A & C 
B& C 
 
0.0001 Significant 
0.0001 Significant 
0.0001 Significant 
0.7675 Not  Significant 
 
In group A the range of sedation score was 1-2 
In group B the range of sedation score was 2-3 
In group C the range of sedation score was 2-3 
In group B and group C the sedation score was higher compared to 
group A. 
DISCUSSION 
Ketamine and midazolam are two important anaesthetic drug 
which are administered in various routes. Ketamine as slow 
inrathecal agent was used by Bion and colleagues in 1984.Kathirvel 
and colleagues were the first to use ketamine with local anaesthetics 
intrathecally. 
Spinal ketamine binds to the phencyclidine site of the NMDA  
receptor gated calcium channel and inhibits the NMDA receptors 
non competitively.Its direct axonal blocking effect produces some 
local anaesthetic activity. 
 Intrathecal midazolam has been shown to have analgesic 
properties and potentiates the effects of local anaesthetics. It is an 
agonist at the benzodiazepine site on a subunit of the pentomeric 
GABA a  receptor. Midazolam tends to suppress afferent evoked 
excitation in the substantia gelatinosa and motor horn of the spinal 
cord. 
Bharti and colleagues had found that postoperative pain Scores 
were lower in patients who received intrathecal midazolam with 
bupivacaine. 
Kim and colleagues used intrathecal midazolam in doses of 1 
and 2 mg along with bupivacaine and found that the duration of 
postoperative analgesia was significantly prolonged by addition of 
intrathecal midazolam and was dose dependent. 
 In this study addition of ketamine and midaolam to 
bupivacaine (Group C) prolongs the duration of sensory and motor 
blockade. The mean pain free period was also significantly 
prolonged. The number of reserve analgesics were comparatively 
less .This finding is consistent with the study done by T.Murali 
Krishna and colleagues who used low doses of ketamine and 
midazolam  with bupivacaine for orthopaedic surgeries. 
In this study addition of ketamine to bupivacaine (Group B) 
does not alter significantly the time for onset or duration of sensory 
and motor blockade.The duration of pain free period was also less 
compared to the midazolam. Ketamine group. This finding is 
consistent with the study done by T.Muralikrishna and colleagues. 
Kathirvel and colleagues showed that combination of ketamine with 
bupivacaine does not prolong postoperative analgesia. 
This infers that midazolam in ( dose 0.02 mg /kg ) when added 
to ketamine in dose (0.1 mg/kg) and bupivacaine prolongs 
significantly the duration of post operative analgesia. This  might be 
due to synergistic action of intrathecal midazolam. Ketamine and 
bupivacaine. 
In this study addition of low dose of ketamine with bupivacaine 
(group B) resulted in stable  haemodynamics with decreased 
incidence of hypotension. This finding is consistent with the 
previous studies by T.Murali Krishna and colleagues,  Kathirvel and 
colleagues and Bion and colleagues.This may be due to diffusion of 
ketamine into the venous system of spinal cord which in turn results 
in cardiovascular stimulation and hemodynamic stability after spinal 
anesthesia. 
In this study the level of sedation was assessed by Ramsay 
sedation score. The level of sedation at 15  and 30 min after the 
block was higher in Group B and C compared to Group A . The 
maximum level of sedation observed is any patient was 3.No patient 
required any manoeuvre to maintain airway. Thus intrathecal 
midazolam and ketamine in low doses had minimal  effect on the 
level of sedation. This finding is consistent with the observation 
made by T.Murali Krishna and colleagues 
 
 SUMMARY 
 
 This study is conducted in patients of ASA I and II undergoing 
elective infraumbilical surgeries.   
3 groups with 30 cases each were selected. Group A received 
0.5% bupivacaine 3 ml with 0.5ml normal saline. 
Group B received 0.5% bupivacaine 3ml with 0.1 mg / kg 
ketamine and the volume made upto 3.5 ml with normal saline. 
Group C received 0.5% bupivacaine 3 ml with 0.1mg/kg 
ketamine and 0.02mg/kg midazolam and the volume made upto 
3.5ml with normal saline. 
The post operative analgesia was significantly prolonged in 
group C with decreased requirement of rescue analgesics over a 24 
hour period.  There was haemodynamic stability in group ‘B’ which 
used ketamine along with bupivacaine whereas   Group A and Group 
C required vasopressors.  The duration of the post operative 
analgesia was not prolonged in group B. 
 
 
  
 
 
 
CONCLUSION 
 
From the study it was concluded that low doses of preservative 
free ketamine (0.1mg/kg) and midazolam (0.02mg/kg) when added 
to bupivacaine intrathecally provides prolonged post operative 
analgesia without any significant side effects. 
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 PROFORMA 
 
NAME  :       HT : 
AGE/SEX  :       WT: 
DATE  : 
IP NO  : 
ASA   : 
DIAGNOSIS : 
Group A :  0.5%  Bupivacaine 3.0ml 
Group B : 0.5%  Bupivicaine 3.0ml+Inj. Ketamine 0.1 mg/kg 
Group C : 0.5%  Bupivicaine 3.0ml+Inj. Ketamine 0.1mg/kg+Inj 
    Midazolam 0.02mg/kg 
Premedication : inj. Atropine 0.6mg + Inj. Midazolam2 mg IM 
SPINAL NEEDLE GAUGE:    Interspace : 
Time of 
SAB 
Onset of sensory 
block (Time of 
injection to height 
at T10 level 
Max. height 
of sensory 
block  
(at 20 min) 
Onset of motor 
block (time of 
injection to 
complete motor 
block) 
Time to 
reach 2 
segment 
regression 
  
 
 
 
   
 
SEDATION SCORE (RAMSAY) 
 
S. 
No. 
 0 
min
15 
min
30 
min
1 
hr 
1 ½  
hr 
2 
hrs 
2 ½ 
hrs 
3 
hrs 
1. Anxious and agitated         
2 Co-operative         
3. Asleep but brisk 
response to loud voice
        
4. Asleep with sluggish 
response to loud voice
        
5. No response to loud 
voice 
        
6. No response to pain         
 
HAEMODYNAMICS: 
Time HR NIBP SPO2 Vasopressor 
Pre-op     
SAB     
5 min     
10 min     
15 min     
20 min     
30 min     
40 min     
50 min     
1 hr     
1 ½ hr     
2 hrs     
2 ½ hrs     
3 hrs     
DURATION OF SURGERY: 
          
VRS  
1-10 
         
 
MOTOR (MODIFIED BROMAGE SCALE): 
Time           
0.No motor loss          
Inability to flex hip          
Inability to flex knee 
joint 
         
Inability to flex ankle          
 
OFFSET OF SENSORY BLOCK (PINPRICK SENSATION AT S2  
  DERMATOME HAS RETURNED) 
OFFSET OF MOTOR BLOCK  
(Complete recovery from motor block-score 0)  
DURATION OF SENSORY BLOCK 
DURATION OF MOTOR BLOCK 
TIME OF RESCUE ANALGESIA  
TIME TO VOID URINE  
TIME OF PAIN FREE INTERVAL 
MEDICATION – inj. ATROPINE 0.6 mg i.v. if PR 60/min 
    If systolic pressure <90mm Hg or below 20% of 
base line MAP Give inj.  Ephedrine and rush IV fluids. 
 
  
 
 
 
  
 
 
 
STRUCTURE OF BUPIVACAINE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
STRUCTURE OF MIDAZOLAM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
STRUCTURE OF KETAMINE 
 
 
 
 
 
 
 
 
 
AGE DISTRIBUTION
7
16
5
2
2
20
7
1
4
6
10
10
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group A Group B Group C
Upto 30 years 31-40 41-50 > 50 yrs
SEX  DISTRIBUTION
24
6
21
9
25
5
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group A Group B Group C
MALE FEMALE
WEIGHT
59.4 62.7 62.9
0
5
10
15
20
25
30
35
40
45
50
55
60
65
W
ei
gh
t (
in
 k
gs
)
Group A Group B Group C
ASA
23
7
25
5
25
5
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group A Group B Group C
ASA
I II
SYSTOLIC B.P.
117.6
120.1
122.2
0 10 20 30 40 50 60 70 80 90 100 110 120 130
Systolic B.P.
Group A
Group B
Group C
MINIMUM SYSTOLIC B.P.
95.4
104.7
94.9
80 85 90 95 100 105 110
Minimum systolic B.P.
Group A
Group B
Group C
VASOPRESSOR
16
14
4
26
14
16
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group A Group B Group C
YES NO
ONSET OF SENSORY BLOCK 
5.55
7.2
3.92
0
1
2
3
4
5
6
7
8
O
ns
et
 o
f s
en
so
ry
 b
lo
ck
 (i
n 
m
in
ut
es
)
Group A Group B Group C
ONSET OF MOTOR BLOCK 
8.55
8.55
6.78
5
6
7
8
9
10
O
ns
et
 o
f m
ot
or
 b
lo
ck
  (
in
 m
in
ut
es
)
Group A Group B Group C
MAXIMUM SENSORY LEVEL
0 4 16 10
0 4 16 10
3 21 6
0
0% 20% 40% 60% 80% 100%
Group A
Group B
Group C
T2 T4 T6 T8
SEDATION SCORE
5
25
0
0
8
22
0
7
23
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Group A Group B Group C
SEDATION SCORE
1 2 3
DURATION OF SENSORY BLOCK
199.7 207
266.3
0
50
100
150
200
250
300
D
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at
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n 
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or
y 
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oc
k
(in
 m
in
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)
Group A Group B Group C
DURATION OF MOTOR BLOCK
159.7
181.3
208.7
100
120
140
160
180
200
220
D
ur
at
io
n 
of
 m
ot
or
 b
lo
ck
(in
 m
in
ut
es
)
Group A Group B Group C
DURATION OF 
PAIN FREE INTERVAL
303 296
473
0
50
100
150
200
250
300
350
400
450
500
D
ur
at
io
n 
of
 p
ai
n 
fr
ee
 in
te
rv
al
(in
 m
in
ut
es
)
Group A Group B Group C
NUMBER OF 
RESCUE ANALGESICS
2.37
1.57
1
0
0.3
0.6
0.9
1.2
1.5
1.8
2.1
2.4
2.7
3
N
um
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r 
of
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cu
e 
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Group A Group B Group C
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S
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e
 
N
o
.
1 A 35 F 50131 164 52 I 120 80 90 YES 5 8 T6 2 180 160 240 2
2 A 44 M 51291 160 48 I 116 74 98 NO 5.5 8.5 T8 2 200 150 300 2
3 A 38 M 6108 155 60 I 128 72 98 NO 5 8 T6 2 220 180 360 3
4 A 38 M 7432 165 55 II 116 70 104 NO 4.5 9 T8 2 210 160 300 3
5 A 40 M 50041 172 58 II 120 68 106 NO 5 8.5 T8 2 210 170 320 2
6 A 42 M 54931 168 54 I 118 74 110 NO 5.5 9 T6 2 180 180 300 3
7 A 36 F 49791 155 52 I 124 80 104 NO 6 10 T4 2 210 160 310 2
8 A 28 M 5164 170 56 I 120 78 110 NO 6.5 9 T8 2 210 170 320 3
9 A 26 M 53001 175 58 I 118 74 104 NO 5.5 8.5 T6 2 180 180 310 2
10 A 28 M 49821 170 62 I 124 78 106 NO 6 8.5 T8 2 200 180 300 3
11 A 30 F 5675 164 60 I 120 64 90 YES 5.5 8 T4 2 210 170 320 3
12 A 32 F 49381 160 65 I 104 70 86 YES 5 8 T6 2 180 160 300 2
13 A 34 M 51061 158 60 I 108 68 88 YES 4.5 8.5 T6 2 210 180 240 2
14 A 28 M 50032 170 65 I 110 70 84 YES 5 8 T6 2 200 150 280 2
15 A 30 M 41161 172 64 I 108 66 88 YES 5.5 8.5 T8 2 210 160 300 2
16 A 35 M 40113 160 50 I 120 70 90 YES 5 8 T8 2 180 160 480 2
17 A 30 F 45113 154 55 I 130 68 90 YES 5.5 7.5 T6 2 200 160 360 2
18 A 36 M 6013 170 60 I 126 80 90 YES 6 8.5 T6 2 220 160 480 2
19 A 35 F 4972 155 62 II 128 70 104 NO 5.8 8.8 T6 2 210 150 420 2
20 A 38 M 5610 165 70 I 129 74 90 YES 6 9.5 T8 1 180 160 420 2
21 A 32 M 64101 168 72 I 130 68 92 YES 6.5 8.6 T4 2 190 100 480 2
22 A 40 M 51612 170 75 II 120 70 90 YES 5.5 7.5 T6 1 200 150 360 2
23 A 48 M 43211 172 68 I 110 70 100 NO 5.8 8.8 T8 1 210 160 390 2
24 A 60 M 6408 168 74 I 106 74 102 NO 6 9.5 T4 2 220 140 420 2
25 A 63 M 41151 170 68 II 108 68 104 NO 6.5 8 T6 2 240 150 400 3
26 A 50 M 6009 164 49 I 110 70 90 YES 5.5 8.6 T6 1 200 170 380 2
27 A 48 M 43211 168 55 II 117 74 90 YES 5 8.8 T6 1 210 160 360 3
28 A 36 M 5631 170 48 I 118 68 88 YES 5.8 8.5 T8 2 180 160 540 3
29 A 38 M 6009 165 50 I 114 70 86 YES 6 8 T6 2 160 150 420 3
30 A 40 M 7104 168 56 II 108 68 90 NO 5.5 10 T6 2 180 150 480 3
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31 B 50 M 40329 168 50 I 120 80 120 NO 4 8 T6 3 180 160 300 1
32 B 40 F 50321 156 56 I 124 78 108 NO 5 8.5 T8 2 200 150 240 2
33 B 35 M 40621 170 60 I 120 80 110 NO 3.5 8 T6 3 220 180 360 2
34 B 60 F 3990 165 62 II 120 74 114 NO 4 9 T8 3 210 160 300 1
35 B 45 M 4086 170 63 I 128 80 106 NO 5 8.5 T8 3 210 170 200 1
36 B 44 F 51002 156 70 I 126 80 98 NO 5 9 T6 3 180 180 360 2
37 B 35 M 3409 160 72 I 124 84 94 NO 4.5 10 T4 3 210 160 300 2
38 B 36 F 7186 149 58 I 120 80 96 NO 4 9 T8 2 210 170 300 1
39 B 40 M 4009 156 68 II 110 70 104 NO 3.8 8.5 T6 3 180 180 240 2
40 B 45 M 41321 154 70 I 116 70 110 NO 10 8.5 T8 3 200 180 270 2
41 B 38 M 51026 165 72 II 114 70 102 NO 9 8 T4 2 210 170 280 2
42 B 34 M 53029 172 68 I 116 72 104 NO 8.3 8 T6 3 180 160 320 2
43 B 42 F 54011 160 70 I 114 80 102 NO 8.5 8.5 T6 3 210 180 300 2
44 B 50 M 51102 163 68 I 118 78 100 NO 8 8 T6 3 200 150 340 2
45 B 49 M 5006 149 66 I 120 76 98 NO 9 8.5 T8 3 210 200 320 2
46 B 35 F 10064 165 45 I 120 80 98 NO 7.5 8 T8 2 180 200 300 2
47 B 40 M 2019 160 58 I 116 78 104 NO 8 7.5 T6 2 200 180 320 2
48 B 35 M 51132 172 60 I 118 80 110 NO 7.5 8.5 T6 3 220 200 300 2
49 B 40 M 50096 168 64 I 120 72 116 NO 8 8.8 T6 3 210 160 280 2
50 B 36 F 51121 169 68 I 124 78 120 NO 8.5 9.5 T8 3 180 180 280 2
51 B 35 M 5493 154 64 I 117 76 116 NO 9 8.6 T4 2 190 200 280 1
52 B 38 M 56001 155 62 I 118 78 104 NO 8 7.5 T6 3 200 200 300 1
53 B 28 M 53009 158 65 I 136 80 110 NO 8.5 8.8 T8 3 210 160 320 1
54 B 29 F 4319 164 63 II 128 78 108 NO 9 9.5 T4 2 220 200 300 1
55 B 34 M 8614 156 58 I 126 74 110 NO 10 8 T6 3 240 240 310 2
56 B 36 M 7493 172 55 I 118 72 106 YES 8.5 8.6 T6 3 200 200 280 1
57 B 34 F 10012 198 59 I 116 74 90 YES 8 8.8 T6 2 210 190 310 1
58 B 35 M 53012 154 61 I 120 78 88 YES 9 8.5 T8 3 280 200 300 1
59 B 33 M 4753 160 55 I 116 74 92 YES 7.5 8 T6 3 220 200 280 1
60 B 32 M 6192 175 72 II 120 78 104 NO 7.5 10 T6 3 240 180 300 1
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61 C 41 M 55003 170 60 I 130 90 90 YES 4 7 T4 3 240 200 480 1
62 C 23 M 47753 168 60 I 120 80 100 NO 5 7.5 T4 3 300 240 480 1
63 C 42 F 48413 155 50 I 130 90 100 NO 5 7 T4 3 240 200 420 1
64 C 53 M 39180 160 60 I 110 70 106 NO 4 6.5 T6 3 250 240 480 1
65 C 35 M 50084 165 50 I 112 86 98 NO 3.5 7 T4 3 280 200 420 1
66 C 51 M 36794 160 65 I 142 80 80 YES 3.8 7 T4 2 300 240 900 1
67 C 51 M 38608 165 66 II 130 90 82 YES 4 7.5 T4 3 300 220 720 1
68 C 53 M 2896 168 55 I 126 84 90 YES 5 6 T4 3 300 180 480 1
69 C 61 M 8441 169 65 II 136 82 92 YES 4 6.5 T6 2 300 220 480 1
70 C 55 F 34278 173 76 I 130 80 90 NO 3.5 7 T4 3 240 200 420 1
71 C 23 M 49224 158 53 II 126 80 100 NO 3 7.5 T6 3 240 200 360 1
72 C 41 M 45493 170 58 I 112 76 104 NO 4 6.5 T4 3 240 180 420 1
73 C 32 M 47266 157 59 II 110 78 110 NO 3.5 7 T4 3 240 200 480 1
74 C 24 M 3440 169 72 I 106 80 104 NO 4 7.5 T4 3 300 220 360 1
75 C 43 M 36506 159 73 II 120 78 102 NO 3.8 7 T4 2 360 240 900 1
76 C 35 M 56012 160 65 I 120 70 90 YES 4 7.5 T4 3 360 240 480 1
77 C 43 M 35079 165 76 I 128 80 92 YES 4 6.5 T4 3 240 200 360 1
78 C 52 M 39675 170 72 I 130 90 90 YES 5 7 T6 3 200 180 480 1
79 C 43 F 50167 160 55 I 126 82 90 YES 3.5 7.5 T4 3 240 160 420 1
80 C 54 M 50241 158 58 I 140 86 86 YES 4 7 T4 3 200 180 420 1
81 C 34 M 52047 163 50 I 128 80 92 YES 3.5 7.5 T2 3 300 200 480 1
82 C 31 M 50076 172 68 I 130 78 88 NO 4 7 T4 2 240 220 360 1
83 C 42 M 52113 160 64 I 128 68 104 NO 4 6 T2 2 280 240 390 1
84 C 43 M 50019 158 60 I 126 90 102 NO 3.8 6.5 T4 3 300 220 420 1
85 C 25 M 54855 160 65 I 106 80 100 NO 3.5 7 T6 2 240 200 400 1
86 C 41 F 50013 170 60 I 112 78 104 NO 3.5 6.5 T4 3 200 180 380 1
87 C 43 M 50019 165 70 I 108 70 82 YES 3.5 6 T2 3 240 200 360 1
88 C 52 F 50632 153 65 I 116 72 102 NO 3.5 6 T4 2 280 220 540 1
89 C 53 M 4963 175 68 I 115 72 88 YES 3.8 5.5 T4 3 300 240 420 1
90 C 31 M 5128 172 68 I 114 74 90 YES 4 5.5 T6 3 240 200 480 1
